Avacta Group PLC Block Listing Six Monthly Return (4522R)
October 27 2023 - 1:00AM
UK Regulatory
TIDMAVCT
RNS Number : 4522R
Avacta Group PLC
27 October 2023
27 October 2023
Avacta Group plc
("Avacta" or "the Group" or "the Company")
Block Listing Six Monthly Return
Avacta Group plc (AIM: AVCT), a life sciences company focused on
improving healthcare outcomes through targeted cancer treatments
and diagnostics, today makes the following notification pursuant to
Schedule Six of the AIM Rules for Companies regarding its existing
block admission arrangements:
Name of applicant: Avacta Group plc
Name of scheme: EMI scheme
--------------------------------
Period of return: From: 28 April 2023 27 October 2023
----------- -------------- ----------------
Balance of unallotted securities
under scheme(s) from previous
return: 414,178
--------------------------------
Plus: The amount by which the
block scheme(s) has been increased
since the date of the last return
(if any increase has been applied
for): 600,000
--------------------------------
Less: Number of securities issued/allotted
under scheme(s) during period
(see LR3.5.7G): 216,256
--------------------------------
Equals: Balance under scheme(s)
not yet issued/allotted at end
of period: 797,922
--------------------------------
Name of applicant: Avacta Group plc
Name of scheme: LTIP scheme
--------------------------------
Period of return: From: 28 April 2023 27 October 2023
----------- -------------- ----------------
Balance of unallotted securities
under scheme(s): 2,370,589
--------------------------------
Plus: The amount by which the
block scheme(s) has been increased
since the date of the last return
(if any increase has been applied
for): 3,700,000
--------------------------------
Less: Number of securities issued/allotted
under scheme(s) during period
(see LR3.5.7G): 793,332
--------------------------------
Equals: Balance under scheme(s)
not yet issued/allotted at end
of period: 5,277,257
--------------------------------
Name of contact: Tony Gardiner, Company Secretary
Telephone number of contact: + 44 (0) 1904 217070
---------------------------------
Ends-
For further information from Avacta Group plc, please
contact:
Avacta Group plc Tel: +44 (0) 1904 21 7070
Alastair Smith, Chief Executive www.avacta.com
Officer
Tony Gardiner, Chief Financial Officer
Michael Vinegrad, Group Communications
Director
Stifel Nicolaus Europe Limited (Nomad Tel: +44 (0) 207 710 7600
and Joint Corporate Broker) www.stifel.com
Nicholas Moore / Nick Adams / Samira
Essebiyea / Nick Harland / William
Palmer-Brown
Peel Hunt (Joint Corporate Broker) Tel: +44 (0) 207 418 8900
James Steel / Chris Golden / Patrick www.peelhunt.com
Birkholm
ICR Consilium (Media and IR) avacta@consilium-comms.com
Mary-Jane Elliott / Jessica Hodgson
/ Sukaina Virji
About Avacta Group plc - https://www.avacta.com
Avacta Group is a UK-based company focused on improving
healthcare outcomes through targeted cancer treatments and
diagnostics.
Avacta has two divisions: an oncology biotech division
harnessing proprietary therapeutic platforms to develop novel,
highly targeted cancer drugs, and a diagnostics division, which is
executing on an M&A led growth strategy to create a
full-spectrum diagnostics business focused on supporting healthcare
professionals and broadening access to testing. Avacta's two
proprietary platforms, Affimer(R) and pre|CISION(TM) underpin its
cancer therapeutics whilst the diagnostics division leverages the
Affimer(R) platform to drive competitive advantage in its
markets.
The pre|CISION(TM) platform modifies chemotherapy to be
activated only in the tumour tissue, reducing systemic exposure and
toxicity. This is achieved by harnessing an enzyme called FAP which
is highly upregulated in most solid tumours compared with healthy
tissues, turning chemotherapy into a "precision medicine". The lead
pre|CISION(TM) programme, AVA6000 a tumour activated form of
doxorubicin, is in Phase 1 studies and has shown dramatic
improvement in safety compared with standard doxorubicin, and early
signs of clinical activity.
Affimer(R) is a novel biologic platform which has significant
technical and commercial advantages compared with antibodies and is
used both to develop advanced immunotherapies and to improve the
performance of immunodiagnostics.
With a balanced business and capital allocation model: a
high-value oncology pipeline supported by a revenue generating,
fast-growing diagnostics business, Avacta seeks to create long-term
shareholder value alongside patient benefit.
To register for news alerts by email go to
https://avacta.com/investors/investor-news-email-alerts/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BLRPPGQPUUPWGAQ
(END) Dow Jones Newswires
October 27, 2023 02:00 ET (06:00 GMT)
Avacta (LSE:AVCT)
Historical Stock Chart
From Apr 2024 to May 2024
Avacta (LSE:AVCT)
Historical Stock Chart
From May 2023 to May 2024
